The implication of RAS was confirmed by the successful therapeutic use of RAS inhibitors and RAS receptor blockers in inhibiting the onset of diabetes complications, and also enhancing insulin sensitivity associated with decreased adipocyte size and increasing transcapillary glucose transport (Ribeiro-Oliveira et al., 2008). The gene discussed is INS; the disease is diabetes mellitus.